Abstract DP299: Oral antithrombotic therapy for patients with stroke and active cancer: A secondary analysis of BAT 2 study
Rattachement africain : jp. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Introduction: Patients with ischemic stroke (IS) or transient ischemic attack (TIA) who also have cancer are at risks for ischemic and bleeding events, and mortality. The optimal oral antithrombotic therapy for secondary stroke prevention in patients with cancer remains unclear. This study aimed to reveal the differences in recurrent IS, major bleeding (MB), and all-cause mortality in patients with IS/TIA who had with cancer. Methods: In this investigator-initiated, prospective, multicenter, observational study, patients with cerebrovascular or cardiovascular diseases, who were taking oral antiplatelet and/or anticoagulant agents, were enrolled from October 2016 to April 2019. For this secondary analysis, we collected data on patients with IS/TIA receiving oral antithrombotic therapy for secondary stroke prevention. Patients with uncured cancer was defined as active cancer (AC) and others as non-cancer groups. Results: Of the 4,727 patients (median age: 72 [IQR: 65–79] years; 1,561 [33.0%] women) with IS/TIA, 91 (1.9%) had AC. Of all patients, 3,354 were treated with antiplatelet agent [65, 1.9% with cancer], 1,134 patients to anticoagulant agent [17, 1.5%], and 239 patients to combination therapy [9, 3.8%]. The 1-year rates of recurrent IS (3.4% vs. 2.5%, HR 1.20, 95%CI 0.45-3.24) and MB (0% vs. 1.1%, HR 1.32, 95%CI 0.33-5.39) were not significantly different between AC and non-cancer groups. However, the 1-year mortality rate was significantly higher in the AC than non-cancer group (7.7% vs. 2.1%, HR 5.61, 95%CI 3.41-9.24). In the AC group (median age: 78 [IQR: 70–83] years; 26 [28.6%] women; 65 patients to antiplatelet; 17 anticoagulant; 9 combination], the 1-year rates of recurrent IS (3.2%, 5.9%, 0%), MB (3.2%, 5.9%, 0%) and mortality (4.6%, 17.6%, 11.1%) were not significantly different between antiplatelet, anticoagulant, and combination therapy, respectively. The multivariable Cox regression analysis revealed that female (aHR 0.13, 95%CI 0.02-0.76), dyslipidemia (aHR 0.19, 95%CI 0.04-0.83), CRP (aHR 1.45, 95%CI 1.16-1.80) and D-dimer (aHR 1.17, 95%CI 1.05-1.31) were independent predictor of mortality. Conclusion: Patients with IS/TIA and AC had a higher risk of mortality than those without cancer. The type of oral antithrombotic agent was not associated with recurrent IS, MB or mortality.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Abstract DP299: Oral antithrombotic therapy for patients with stroke and active cancer: A secondary analysis of BAT 2 study
- Date Crossref
- 01/02/2026
- Éditeur
- Ovid Technologies (Wolters Kluwer Health)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Kyorin University pays non établi dans la noticeUniversité ou école supérieure
-
National Cerebral and Cardiovascular Center pays non établi dans la noticeÉtablissement de santé
-
Nagasaki University Hospital pays non établi dans la noticeÉtablissement de santé
-
Jichi Medical University pays non établi dans la noticeUniversité ou école supérieure
-
St. Marianna University School of Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Kawasaki Medical School pays non établi dans la noticeUniversité ou école supérieure
-
Toyota Memorial Hospital pays non établi dans la noticeÉtablissement de santé
-
Kansai Medical University pays non établi dans la noticeUniversité ou école supérieure
-
ST MARIANNA UNIVERSITY pays non établi dans la noticeUniversité ou école supérieure
Kyorin University, National Cerebral and Cardiovascular Center et Nagasaki University Hospital, avec 6 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.